Current value and future potential of biological markers in breast cancer

Journal of B.U.ON.

Volumn 7, Issue 4, 2002, Pages 319-323

  Leake, Robin ^a   Filipovic S ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF NI   (Serbia)

Author keywords

Biological markers; Breast cancer; Estrogen receptor; Progesterone receptor

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CADHERIN; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; FLUOROURACIL; FLUTAMIDE; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; PHOSPHOLIPASE C; PROGESTERONE RECEPTOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN C FOS; PROTEIN C JUN; PROTEIN TYROSINE KINASE; RAF PROTEIN; RAS PROTEIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOS PROTEIN; STEROID RECEPTOR; TAMOXIFEN; TRASTUZUMAB; UNINDEXED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST TUMOR; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE CLASSIFICATION; DRUG EFFECT; ENZYME ACTIVITY; HEALTH CARE COST; HUMAN; MULTIMODALITY CANCER THERAPY; ONCOGENE; PROSTATE CANCER; REVIEW; TREATMENT OUTCOME;

EID: 0037987897     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment with illustrative cases. Lancet 1896; ii: 104-107.
2. Lemon HM, Wotiz HH, Pearsons L, Mozden PJ. The development of a urinary discriminant to identify patients with endocrine-sensitive breast cancer. JAMA 1966; 196: 1128-1136.
3. Jensen EV, Jacobson HI, Flesher JW et al. Estrogen receptors in target tissues. In: Pincus G, Nakao T, Tait JF (eds): Steroid Dynamics. NY: Academic Press, 1966, pp 133-156.
4. Leake RE. Steriod receptor assays in the management of endocrine disorders. Ligand Rev 1981; 3: 23-35.
5. Hawkins RA, Roberts MM, Forest APM. Oestrogen receptors and breast cancer: Current status. Br J Surg 1980; 6: 153-169.
6. Leake RE, Laing L, Calman KC, Macbeth FR, Crawford D, Smith DC. Oestrogen receptor status and endocrine therapy of breast cancer: Response rates and status stability. Br J Cancer 1981; 43: 59-66.
7. Fisher B, Redmond C, Brown A et al. Influence of tumour estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol 1983; 1: 227-241.
8. Thorpe S, Rose C. Oestrogen and progesterone receptors in breast cancer. Cancer Surveys 1986; 5: 505-525.
9. Knight WA, Livingston RB, Gregory EJ, Maguire WL. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 1977; 37: 4660-4671.
10. Early Breast Cancer Trialists Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 1998; 351: 1451-1467.
11. Koenders A, Thorpe S. Standardisation of steroid receptor assays in human breast cancer II. Eur J Cancer 1983; 19: 1467-1472.
12. Barnes DM, Millis RR, Beex LVAM, Thorpe SM, Leake RE. Increase use of immunohistochemistry for oestrogen receptor measurement in mammary carcinoma: The need for quality assurance. Eur J Cancer 1998; 34: 1677-1682.
13. Harvey JM, Clark GM, Osborne CK et al. Estrogen receptor status by immunohistochemistry is superior to the ligand binding assay for predicting response to adjuvant therapy in breast cancer. J Clin Oncol 1999; 17: 1474-1485.
14. Barnes DM, Millis RR, Beex LVAM, Thorpe SM, Leake RE. Increased use of immunohistochemistry for oestrogen receptor measurement in mammary carcinoma: The need for quality assurance. Eur J Cancer 1998; 34: 1677-1682.
15. Rhodes A. External quality assessment of immunocytochemistry: UK NEQAS review of run 52. Cell Pathol 2001; 5: 253-293.
16. Crawford DJ, Cowan S, Fitch R, Smith DC, Leake RE. Stability of oestrogen receptor status in sequential biopsies from patients with breast cancer. Br J Cancer 1987; 56: 137-140.
17. Jordan, VC, Morrow M. Tamoxifen, raloxifene and the prevention of breast cancer. Endocrine Rev 1999; 20: 253-278.
18. Nicholson S, Halcrow P, Farndon JR, Sainsbury JRC, Chambers P, Harris AL. Expression of epidermal growth factor receptors is associated with lack of response to endocrine therapy in recurrent breast cancer. Lancet 1989; i: 182-185.
19. Jones HE, Dutkowski CM, Barrow D, Harper ME, Wakeling AE, Nicholson RI. New EGF-R selective tyrosine kinase inhibitor reveals variable growth responses in prostate carcinoma cell lines PC-3 and DU-145. Int J Cancer 1997; 71: 1010-1018.
20. Leake RE. The cell cycle. In: SC Hillier, HC Kitchener, JP Nielson (eds): Scientific Essential of Reproductive Medicine. WB Saunders, 1996, pp 26-31.
21. Lloyd SN, Chalmers D, Leake RE, Kirk D. Local hyperthermia for prostatic disease: In vitro studies on human prostatic cell lines. Br J Urol 1992; 70: 529-534.
22. Stal O, Sullivan S, Wingren S et al. c-erbB 2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur J Cancer 1995; 31A: 2185-2190.
23. Schmitt M, Harbeck N, Thomssen C et al. Clinical impact of the plasminogen activator system in tumour invasion and metastasis: Prognostic relevance and target for therapy. Thromb Haemostasis 1997; 78: 285-296.
24. Sweep CGJ, Guerts-Moespot J, Grebenschikov N et al. External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts. Br J Cancer 1998; 78: 1434-1441.